Research digest
Semax: thirty years of Russian neuropeptide research, indexed from the primary sources.
A heptapeptide derived from ACTH fragment 4-10. Approved as a pharmaceutical in the Russian Federation since 1994. Studied in ischemia, BDNF modulation, cognitive performance, and neuroprotection. The literature is reproduced here — finding by finding, citation by citation.
What the Semax literature has documented
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone, specifically positions 4 through 10.[1] It does not carry the steroidogenic activity of full ACTH. The compound has been studied in rodent ischemia models, in vitro cell culture systems, behavioral paradigms, and a limited body of Eastern European observational clinical work.
The research literature on Semax is predominantly Russian in origin, produced at the Institute of Molecular Genetics of the Russian Academy of Sciences and affiliated institutions across four decades. That provenance matters: it means the compound has been studied rigorously in one scientific tradition, while independent Western replication in randomized controlled trials remains sparse. Both facts belong in the same sentence.
The headline mechanistic findings are well-replicated within the Russian literature: Semax binds melanocortin receptor MC4R with nanomolar affinity, upregulates BDNF and NGF mRNA rapidly in hippocampal and glial cells, and inhibits enkephalin-degrading serum enzymes.[1][2][7][10] A single intranasal dose of 50 µg/kg produced a 3-fold increase in BDNF mRNA in rat hippocampus within hours.[2] Eight-fold elevation of BDNF mRNA was observed in rat basal forebrain glial cultures within 30 minutes.[7]
In ischemia models, Semax at 100 µg/kg (intraperitoneal) suppressed inflammatory gene expression — IL-1a, IL-1b, IL-6, CCL3, and CXCL2 — while upregulating vascular and neurotrophic genes in the peri-ischemic zone.[4][5] A 2025 study identified a previously uncharacterized mechanism: Semax targets the mu-opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.[21]
Registration and approval context: Semax has been approved as a pharmaceutical drug in Russia since 1994 for cerebrovascular indications, cognitive disorders, and optic neuropathy. It is not approved by the FDA or EMA for any indication. It is unscheduled as a controlled substance in the United States as of 2025.
This site documents the research record on Semax. It is an editorial digest, not a clinical service. See the Semax mechanism of action, Semax dosage protocols, and frequently asked questions about Semax for detailed coverage.
What Is Semax Used For in Research?
The Semax research literature clusters around five primary investigative domains.
Cerebral ischemia and stroke recovery. The largest body of work places Semax in rat middle cerebral artery occlusion models, where it consistently suppresses neuroinflammatory gene cascades and promotes expression of neurotrophic and vascular genes.[4][5][6] The compound is approved in Russia for acute ischemic stroke under this basis.
BDNF and neurotrophin modulation. Multiple studies document rapid, dose-dependent upregulation of BDNF mRNA and protein in hippocampal, cortical, and glial cells.[1][2][7][8] TrkB phosphorylation increases in parallel.[2] The BDNF-upregulation findings are among the most replicated in the dataset.
Cognitive performance in rodent models. Semax-treated rats show improved conditioned avoidance reactions consistent with enhanced learning.[2] Dopaminergic and serotonergic modulation in the striatum — including an approximately 25% increase in striatal 5-HIAA at 2 hours post-dosing — underlies proposed attention and memory effects.[3]
Anxiolytic and antidepressant-like effects. In chronic unpredictable stress models, Semax reversed anhedonia, body-weight suppression, adrenal hypertrophy, and decreased hippocampal BDNF.[16] In neonatal deprivation models, Semax normalized anxiety, body weight, and corticosterone stress response.[12][13]
Neuroprotection in injury models. Beyond ischemia, the 2025 spinal cord injury study documents functional recovery improvement via a mu-opioid receptor / USP18 deubiquitination axis.[21] The copper-chelation mechanism is a newer research thread with potential relevance to Alzheimer's-type neurodegeneration models.[20]
See the Semax neuroprotection studies and Semax BDNF research for granular citation-level detail.
Why is Semax studied?
Semax occupies an unusual position in the neuropeptide research landscape: it is a synthetic compound derived from a well-characterized hormone fragment, carries an approved drug record in one national regulatory system, and has accumulated a coherent mechanistic literature — yet remains essentially unknown in Western clinical research.
Researchers study Semax for its potential neuroprotective, nootropic, and anxiolytic properties in rodent models — particularly in stroke recovery, BDNF upregulation, and cognitive task performance.[1][2][4] The compound's dual mechanism — melanocortin receptor binding plus enkephalinase inhibition — gives it a pharmacological profile distinct from either classical nootropics or peptide growth factors.[10]
The 2024 antidepressant-like profile paper and the two 2025 publications (copper chelation, spinal cord injury) suggest the field is expanding its investigative scope beyond cerebrovascular models into neurodegeneration and spinal cord pathology.[16][20][21] That trajectory is documented here.
What does Semax do?
In animal and in vitro models, Semax modulates BDNF expression, inhibits nitric oxide synthesis, and activates dopamine and serotonin signaling pathways associated with attention and memory consolidation.[1][2][3]
At the receptor level, Semax binds MC4R with a dissociation constant (KD) of approximately 2.4 ± 1.0 nM in rat forebrain membranes.[1] Downstream, this activates the cAMP/CREB signaling cascade, driving transcription of BDNF and NGF genes in hippocampal neurons and glial cells.[2][7] Simultaneously, Semax inhibits enkephalin-degrading serum enzymes at an IC50 of approximately 10 µM — prolonging the synaptic lifetime of endogenous opioid peptides.[10]
In striatal circuitry, intranasal Semax at 30 µg/kg produced a roughly 25% increase in striatal 5-HIAA tissue content at 2 hours, with extracellular 5-HIAA gradually rising to approximately 180% within 1-4 hours — indicating enhanced serotonergic turnover.[3]
In ischemic tissue, the molecular signature is distinct: Semax upregulates pCREB, downregulates MMP-9 and c-Fos, and suppresses active JNK in both ischemic and peri-ischemic cortex.[4] In a genome-wide analysis, over 50% of genes significantly altered at 24 hours post-ischemia were immune-function genes, most of which were suppressed.[5]
Recent studies (2024-2025)
Four peer-reviewed publications in 2024 and 2025 extended the Semax literature into new mechanistic territory.
In 2024, Inozemtseva et al. demonstrated that Semax reversed chronic unpredictable stress-induced anhedonia, body-weight suppression, adrenal hypertrophy, and decreased hippocampal BDNF levels in male rats, producing an antidepressant-like profile comparable to the related compound Melanotan II.[16] No significant effect was observed in the forced swim test, indicating a partial, not complete, antidepressant-like profile.
In 2025, Tomasello et al. published a copper-chelation study showing that Semax strips Cu(II) from amyloid-beta complexes with high affinity and reduces ROS-induced cell death by approximately 20-23% in human neuroblastoma cells.[20] The Met and His residues coordinate Cu(II), making copper chelation a mechanistically distinct pathway from the MC4R and enkephalinase mechanisms documented in earlier work.
Also in 2025, Liu et al. identified a spinal cord injury mechanism: Semax targets the mu-opioid receptor gene Oprm1 to promote FTO deubiquitination via USP18, improving Basso scores, footprint analysis, and inclined plane test performance after T9-T10 impact in female mice.[21]
Volodina et al. (2025) localized Semax's hippocampal calcium-signaling activity: 1 µM Semax increased spontaneous Ca2+ fluctuation frequency in CA1 pyramidal neurons without affecting ASIC-mediated calcium entry in cerebellar granule cells, suggesting region-specific hippocampal calcium modulation.[19]
For the complete citation record, see Semax neuroprotection studies and the full references list.